Clinical Research Directory

Inclusion Criteria: 1. Gender and Age: Cisgender women, aged 18 years or older. 2. Surgical Procedure: Participants undergoing primary breast augmentation or benign reconstruction using the following minimally invasive procedures: * Mia Harmonization * Mia Scarless Lift * Mia Reconstruction * Joy Dot * Maxtopexia + Mia 3. Breast Size: Cup sizes AA to C, as determined by guidelines from Triumph International. 4. Health Status: ASA (American Society of Anesthesiologists) classification I or II. 5. Tissue Integrity: Adequate breast tissue available to cover the implant(s). 6. Commitment: Willingness to adhere to all study requirements, including follow-up visits and signing the informed consent form. 7. Special Cases for Reconstruction: Participants with congenital or acquired breast or thoracic conditions, such as amastia, pectus excavatum/carinatum, tuberous breasts, or asymmetry. 8. Mia Scarless Lift Specifics: Participants with mild, moderate, or pseudoptosis based on physician evaluation. 9. Timing: Women scheduled for surgery at the Sulàyöm Innovation Campus between January and December 2025. Exclusion Criteria: 1. Non-Specified Procedures: Women undergoing augmentation or reconstruction with techniques other than those listed (Mia Harmonization, Mia Scarless Lift, Mia Reconstruction, Joy Dot, Maxtopexia + Mia). 2. Non-Study Implants: Use of implants other than Motiva products. 3. Compromised Tissue or Skin: * Existing rib lesions or significant/severe breast ptosis. * Poor tissue quality due to radiation damage, vascular compromise, or prior ulceration. 4. Medical History: * History of breast abscesses or infections. * Sensitivity or allergy to silicone. 5. Current Physiological Conditions: -Pregnancy or breastfeeding, or within six months postpartum or post-lactation. 6. Medications: Use of anticoagulants or medications that impair wound healing (e.g., corticosteroids, Warfarin). 7. Imaging Constraints: Conditions that prevent the use of MRI (e.g., implanted metal devices, claustrophobia). 8. Concurrent Research: Participation in another clinical research study involving drugs or devices. 9. Follow-Up Barriers: Residency outside Costa Rica or inability to attend required follow-up visits. 10. Timing Issues: Participants undergoing surgery outside the designated study period (January to December 2025).